Diagnosis，treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency
WANG Tong, YE Jun, HAN Lian-Shu, QIU Wen-Juan, ZHANG Hui-Wen, ZHANG Ya-Fen, GAO Xiao-Lan, WANG Yu, GU Xue-Fan.
Department of Pediatric Endocrinology and Genetic Metabolism, Shanghai Institute for Pediatric Research, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092,China.
Abstract：OBJECTIVE: To report the clinical diagnosis, treatment and follow-up of children with holocarboxylase synthetas(HCS) deficiency and explore the gene mutation spectrum of the disease. METHODS: Eleven children with HCS deficiency were enrolled. Mass spectrometry analysis and biotinidase activity determination were used for diagnosis of HCS deficiency. HCS gene mutations were analyzed by PCR directed sequencing methods. Ten patients received oral biotin treatment (10-40 mg/d). Clinical effects of biotin treatment were observed. RESULTS: All 11 cases developed apathetic, lethargy and metabolic acidosis at different degrees, and 10 cases presented with skin lesions. The average blood 3-hydroxyisovaleryl-carnitine concentrations and urinary 3-methylcrontonylglycine and methylcitrate concentrations increased significantly. The biotinidase activity increased, being higher over 30% of the normal reference value. Four mutations in HCS gene were identified, and they were c.1522C>T (R508W), c.1088T>A (V363D), c.126G>T (E42D) and c.1994G>C (R665P) (a new variant) and the frequency was 50%, 29%, 7% and 14% respectively. The symptoms disappeared in 10 cases 1-2 weeks after biotin treatment, and blood and urinary abnormal metabolites were gradually reduced to normal 2-6 months after treatment. CONCLUSIONS: HCS deficiency is characterized by nervous system damage, skin lesions and metabolic acidosis. Mass spectrometry analysis, biotinidase activity determination and gene mutation analysis may be helpful in the definite diagnosis of this disorder. The effect of early biotin treatment is satisfactory. The mutations R508W and V363D might be hot-spots in Chinese children with HCS deficiency.［Chin J Contemp Pediatr, 2009, 11 (8):609-612］
WANG Tong,YE Jun,HAN Lian-Shu et al. Diagnosis，treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency[J]. CJCP, 2009, 11(08): 609-612.
［3］Han LS, Ye J, Qiu WJ, Gao XL, Wang Y, Gu XF. Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: a fouryear report［J］.J Inherit Metab Dis, 2007, 30(4):507-514.
［7］Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y. Mutations in the holocarboxylase synthetase gene HLCS ［J］.Hum mutat, 2005, 26(4):285-290.
［8］Wolf B. Disorders of biotin metabolism［M］. //Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular basis of inherited disease.8th ed.New York:McGraw Hill, 2001, 3935-3962.
［10］Morrone A, Malvagia S, Donati MA, Funghini S, Ciani F, Pela I, et al. Clinical findings and biochemical and molecular analysis of four patients with holocarboxylase synthetase deficiency［J］. Am J Med Genet, 2002, 111(1):10-18.
［12］Santer R, Muhle H, Suormala T, Baumgartner ER, Duran M, Yang X, et al. Partial response to biotin therapy in a patient with holocarboxylase synthetase deficiency: clinical, biochemical, and molecular genetic aspects［J］. Mol Genet Metab, 2003, 79(3):160-166.
［13］Dupuis L, Campeau E, Leclerc D, Gravel RA. Mechanism of biotin responsiveness in biotin-responsive multiple carboxylase deficiency［J］. Mol Genet Metab, 1999, 66(2):80-90.
